Evaluation of the relationship between surfactant protein D levels and COVID-19 clinical severity: a case-control study

Basit Öğe Kaydı
dc.contributor.authorKarslı, E.
dc.contributor.authorSabırlı, R.
dc.contributor.authorGören, T.
dc.contributor.authorKemancı, A.
dc.contributor.authorKarış, D.
dc.contributor.authorTürkçüer, İ.
dc.contributor.authorKurt Ö.
dc.date.accessioned2024-05-19T14:33:45Z
dc.date.available2024-05-19T14:33:45Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractPurpose: Serum surfactant protein D (SP-D) plays roles in the body such as protection against viral infection, bacterial and fungal clearance, clearance of apoptotic cells and suppression of inflammation. This study aims to examine the relationship between SP-D level and coronavirus disease (COVID-19) severity. Methods: 80 patients (30 with mild disease and 50 with severe/critical COVID-19), and 50 healthy volunteers were enrolled in the study. SP-D levels were analyzed by ELISA in serum samples. Results: The median of SP-D was found to be 2.47 (1.67-7.79) ng/ml in mild disease and 5.65 (3.09-16.55) ng/ ml in severe/critical disease groups, while 2.89 (10.8-6.24) ng/ml in the healthy controls. The differences in SP-D levels between the severe/critical disease group compared to both mild disease and control groups were found statistically significant (p=0.007 and 0.001, respectively). ROC analysis showed greater AUC for the serum SP-D levels of the severe/critical COVID-19 patients compared to mild COVID-19 disease patients (AUC=0,691, 95% CI=0.56-0,822; p=0.004). Furthermore, SP-D levels were 86% sensitive and 51.6% specific at 2.44 ng/ml level (p=0.004) to detect severe/critical patients. Conclusion: SP-D levels is useful for COVID-19 patients in the prediction of clinical severity and prognosis. SP-D is a valuable biomarker for predicting the clinical severity and prognosis. © 2023, Pamukkale University. All rights reserved.en_US
dc.identifier.doi10.31362/patd.1159512
dc.identifier.endpage147en_US
dc.identifier.issn1309-9833
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85160691719en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage137en_US
dc.identifier.trdizinid1163599en_US
dc.identifier.urihttps://doi.org/10.31362/patd.1159512
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1163599
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4324
dc.identifier.volume16en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherPamukkale Universityen_US
dc.relation.ispartofPamukkale Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCovıd-19en_US
dc.subjectPneumoniaen_US
dc.subjectSerum Surfactant Protein Den_US
dc.titleEvaluation of the relationship between surfactant protein D levels and COVID-19 clinical severity: a case-control studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu